Oslo - April 21, 2023: EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical stage biopharmaceutical company with a mission to enhance the
therapeutic efficacy of medicines through ultrasound-mediated drug delivery,
today announces that its Board of Directors has approved the Annual Report
including the Annual Financial Statements for the year ended 31 December 2022.
The Annual Report for 2022 is also available on the Company's website:
https://www.exact-tx.com/key-information


For more information, please contact: 
Per Walday 

CEO EXACT Therapeutics 

Email: per.walday@exact-tx.com 

John M. Edminson

CFO EXACT Therapeutics

Email: john.edminson@exact-tx.com

About EXACT-Tx 
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted
drug enhancement - with the potential to significantly amplify the clinical
utility of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and brain diseases. www.exact-tx.com